Merck & Cie

Hoffmann-la Roche Inc.

Eth Zuerich

Eidgenoessische Technische Hochschule Zuerich

Novartis Ag

Bayer Pharma Aktiengesellschaft

Unversität Zürich

Merck Eprova Ag

Mereck & Cie

Eidgenössische Technische Hochschule Zürcih

Eth Zurich

F. Hoffmann-la Roche Ag

Eidgenossische Technische Hochschule Zurich

Novartis Pharma Gmbh

Simon Mensah Ametamey

Rudolf Moser

Viola Groehn

Luca Claudio Gobbi

Roger Schibli

Tobias Ludwig Ross

Cristina Magdalena Muller

Uwe Grether

Julian Kretz

Cindy Ramona Fischer

Mark Rogers-Evans

Wolfgang Guba

Thomas Brumby

Yves Auberson

Christoph Ullmer

Keith Graham

Timo Stellfeld

Lutz Lehmann

Dieter Muri

Fabrizio Gasparini

Thomas Hartung

Thomas Leighton Mindt

Cristina Magdalena Mueller

Juergen Fingerle

Kenneth Atz

Ahmed Haider Wahauib

Linjing Mu

Mylene Tania Karramkam

Ananth Srinivasan

Phoebe Lam

Thomas Betzel

Ahmed Haider

Leo Nicholls

Harriet Struthers

Lea Kessler

Detlef Suelzle

Hazem Ahmed

Cristina Magdalena MÜLLER

The invention relates to a compound of formula (I) wherein Aand R-Rare as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

Azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2

The invention relates to a compound of formula (I) wherein A, A, X and R-Rare as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

Pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2

The present invention relates to a compound of formula (I) wherein R, R, and Rare defined as in the description and in the claims. The compound of formula (I) can be used as a radiolabeled ligand.

Radiolabeled cannabinoid receptor 2 ligand

The invention relates to a compound of formula (I) wherein A, Aand R-Rare as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists

The present invention is directed towards newF-folate radiopharmaceuticals, wherein theF isotope is linked via a prosthetic group, more specifically via a prosthetic group having a saccharide group, such as a cyclic mono- or oligosaccharide, preferably based on a pyranoside or furanoside, which is covalently linked to the glutamate portion of a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.

F-saccharide-folates

The present invention is directed towards newF-folate radiopharmaceuticals, wherein fluorine-18 is covalently linked to the glutamate portion of a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of therapy of cancer and inflammatory and autoimmune diseases.

F-labelled folates as PET radiotracers

The present invention is directed towards a new method of synthesis ofF-folate radiopharmaceuticals, wherein fluorine-18 is attached to a pteroate (or folate) or derivative thereof, through direct radiolabeling with[F]fluoride, as well asF-folate radiopharmaceuticals obtained by such method of synthesis and their use in diagnosis and monitoring of cancer therapy and therapy of inflammatory and autoimmune diseases.

F-labelled folates

The present invention is directed towards newF-folate/antifolate analog radiopharmaceuticals, wherein the phenyl group within folate structures has been replaced by anF-heterocycle, their precursors, a method of their preparation, as well as their use in diagnosis of a cell or population of cells expressing a folate-receptor and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.

18F-labelled folate/antifolate analogues

The present invention is directed towards newF-folate radiopharmaceuticals, wherein theF isotope F is linked via a prosthetic group, more specifically via a prosthetic group having a saccharide group, such as a cyclic mono- or oligosaccharide, preferably based on a pyranoside or furanoside, which is covalently linked to the glutamate portion of a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.

[object Object]

The present invention relates to a compound of formula (I) wherein Ris defined as in the description and in the claims. The compound of formula (I) can be used as radiolabeled ligand.

The present invention is directed towards newF-folate radiopharmaceuticals, wherein the fluorine-18 is covalently linked to the aminobenzoyl moiety, which connects the condensed pyrimidine heterocycle to the amino acid portion within folate structures, as well as their precursors and their non-radioactive references, a method of their preparation, as well as their use in diagnosis of a cell or population of cells expressing a folate-receptor and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.

18F-labelled folates

The present invention is directed towards new trifunctional folate-conjugates comprising a folate, an albumin binder and a radionuclide-based therapeutic or diagnostic moiety as well as pharmaceutical compositions thereof, their method of production and their use in diagnostic and therapeutic medical applications, such as diagnostic nuclear imaging and radionuclide therapy.

Folate conjugates of albumin-binding entities

The present invention relates to novel pyridylacetylene derivatives of formula I their preparation, their use as radio-traces/markers and compositions containing them.

Pyridylacetylenes for use as radiotracers and imaging agents

The present invention relates to novel compounds suitable for or already radiolabeled withF, methods of making such compounds and use of such compounds for diagnostic imaging. Such labeled compounds are characterized by Formula II, wherein the substituents G, Q, L, Y and U have the meaning as defined in the specification and claims. 

Growing community of inventors

Zurich, Switzerland

Simon Mensah Ametamey